Triple Negative Breast Cancer

Common Name(s)

Triple Negative Breast Cancer

Triple-negative breast cancer is when the cancerous cells lack estrogen and progesterone receptors, and HER2 protein on cell surfaces. Without these receptors and the HER2 protein, neither hormone therapy nor drug treatments that target the HER2 protein are effective. Also triple-negative breast cancers grow and spread faster than most other breast cancers. For these mentioned reasons, chemotherapy is recommended even at the early onset of the disease.

Source: Advocacy organizations associated with the condition.

 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Triple Negative Breast Cancer" for support, advocacy or research.

Logo
Breast Cancer Connections

We support people touched by breast or ovarian cancer by providing comprehensive, personalized services in an atmosphere of warmth and compassion.

Last Updated: 22 Apr 2014

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Triple Negative Breast Cancer" for support, advocacy or research.

Logo
Breast Cancer Connections

We support people touched by breast or ovarian cancer by providing comprehensive, personalized services in an atmosphere of warmth and compassion.

http://www.bcconnections.org

Last Updated: 22 Apr 2014

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Triple Negative Breast Cancer" returned 337 free, full-text research articles on human participants. First 3 results:

The prevalence of BRCA1/2 mutations of triple-negative breast cancer patients in Xinjiang multiple ethnic region of China.
 

Author(s): Yong Tao Li, Duo Ni, Liang Yang, Qian Zhao, Jiang Hua Ou

Journal:

 

The screening of BRCA1 and BRCA2 mutations is now an established component of risk evaluation and management of familial breast cancer, early-onset breast cancer and bilateral breast cancer patients. There is still some controversy about whether this screening should be done in triple-negative ...

Last Updated: 1 Jul 2014

Go To URL
Bosutinib reduces the efficacy of Dasatinib in triple-negative breast cancer cell lines.
 

Author(s): Mike Tarpley, Temesgen T Abdissa, Gary L Johnson, John E Scott

Journal: Anticancer Res.. 2014 Apr;34(4):1629-35.

 

Triple-negative breast cancer (TNBC) is an aggressive sub-type of breast cancer. Dasatinib and bosutinib are FDA-approved Src/Abl kinase inhibitor drugs. Dasatinib potently inhibits the proliferation of many TNBC cell lines.

Last Updated: 2 Apr 2014

Go To URL
XBP1 promotes triple-negative breast cancer by controlling the HIF1╬▒ pathway.
 

Author(s): Xi Chen, Dimitrios Iliopoulos, Qing Zhang, Qianzi Tang, Matthew B Greenblatt, Maria Hatziapostolou, Elgene Lim, Wai Leong Tam, Min Ni, Yiwen Chen, Junhua Mai, Haifa Shen, Dorothy Z Hu, Stanley Adoro, Bella Hu, Minkyung Song, Chen Tan, Melissa D Landis, Mauro Ferrari, Sandra J Shin, Myles Brown, Jenny C Chang, X Shirley Liu, Laurie H Glimcher

Journal: Nature. 2014 Apr;508(7494):103-7.

 

Cancer cells induce a set of adaptive response pathways to survive in the face of stressors due to inadequate vascularization. One such adaptive pathway is the unfolded protein (UPR) or endoplasmic reticulum (ER) stress response mediated in part by the ER-localized transmembrane sensor ...

Last Updated: 3 Apr 2014

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Triple Negative Breast Cancer" returned 45 free, full-text review articles on human participants. First 3 results:

MicroRNAs and triple negative breast cancer.
 

Author(s): Elvira D'Ippolito, Marilena V Iorio

Journal:

 

Triple Negative Breast Cancer (TNBC) is a very aggressive tumor subtype, which still lacks specific markers for an effective targeted therapy. Despite the common feature of negativity for the three most relevant receptors (ER, PgR and HER2), TNBC is a very heterogeneous disease where ...

Last Updated: 28 Nov 2013

Go To URL
New targets for triple-negative breast cancer.
 

Author(s): Christina I Herold, Carey K Anders

Journal: Oncology (Williston Park, N.Y.). 2013 Sep;27(9):846-54.

 

Triple-negative breast cancer (TNBC) lacks the three most commonly targeted receptors in human breast cancer--the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2)/neu--and it is associated with an aggressive natural history. More ...

Last Updated: 28 Nov 2013

Go To URL
Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes.
 

Author(s): Brian D Lehmann, Jennifer A Pietenpol

Journal: J. Pathol.. 2014 Jan;232(2):142-50.

 

Triple-negative breast cancer (TNBC) is a heterogeneous disease with distinct molecular subtypes that respond differentially to chemotherapy and targeted agents. The absence of high-frequency molecular alterations and a limited number of known biomarkers have limited the development ...

Last Updated: 11 Dec 2013

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

There are currently no related results available in Genetic Testing Registry.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Last Updated: 28 Nov 2012

Go to URL
Patient-derived Xenograft (PDX) Modeling of Treatment Response for Triple Negative Breast Cancer
 

Status: Recruiting

Condition Summary: Triple Negative Breast Cancer

 

Last Updated: 19 Sep 2014

Go to URL
Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast Cancer
 

Status: Not yet recruiting

Condition Summary: Triple-negative Breast Cancer

 

Last Updated: 11 Jun 2014

Go to URL